<DOC>
	<DOCNO>NCT02177786</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability selonsertib ( formerly GS-4997 ) participant diabetic kidney disease ( DKD ) . Participants randomize 1:1:1:1 allocation receive 1 3 dos selonsertib ( 2 mg , 6 mg , 18 mg ) match placebo .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Selonsertib ( GS-4997 ) Participants With Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Key Adult male female prior diagnosis Diabetic Kidney Disease Type 2 diabetes mellitus diagnosis least 6 month eGFR ( MDRD ) screen ≥ 15 mL/min/1.73m^2 &lt; 60 mL/min/1.73m^2 Urine albumin creatinine ratio ( UACR ) follow : Stage/Stratum 3a : eGFR range 45 &lt; 60 mL/min ; UACR ≥ 600 mg/g Stage/Stratum 3b : eGFR range 30 &lt; 45 mL/min ; UACR ≥ 300 mg/g Stage/Stratum 4 : eGFR range 15 &lt; 30 mL/min ; UACR ≥ 150 mg/g Receiving angiotensinconvertingenzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) minimum dose deem appropriate individual investigator stable dose last three month Individuals ACEi/ARB may screen documented intolerance ACE inhibitor and/or ARB Key Type 1 diabetes mellitus Nondiabetic kidney disease UACR &gt; 5000 mg/g measurement screen End stage renal disease ( ESRD ; receive peritoneal dialysis , hemodialysis , status post renal transplantation ) anticipate occur within treatment period Anticipated progression ESRD ( need dialysis list renal transplantation ) within study treatment period Unstable cardiovascular disease Immunosuppressive drug Pregnant lactating female Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetic Kidney Disease</keyword>
	<keyword>Gilead</keyword>
</DOC>